Upgrade to SI Premium - Free Trial

Domo (DOMO) Tops Q2 EPS by 51c, Revenues Beat; Offers FY19 Revenue Outlook Above Consensus

September 6, 2018 4:05 PM

Domo (NASDAQ: DOMO) reported Q2 EPS of ($3.44), $0.51 better than the analyst estimate of ($3.95). Revenue for the quarter came in at $34.3 million versus the consensus estimate of $32.02 million.

Comments“I’d like to thank our employees, customers and investors for helping us achieve the recent milestone of becoming a public company. While we’re early in our journey of fulfilling our vision and realizing our full value, we’re off to a great start. We’re delivering on our top two priorities of focusing on customers and growing the top line, which we’ve grown by more than 30%, and we’re doing so more efficiently,” said Josh James, Domo founder and CEO. “Because Domo can digitally connect any organization and empower each of its employees, we believe our market potential is every working person with a mobile device. The IPO has given us the capital needed to successfully execute our business plan. We are well positioned for future growth.”

“As our unique capabilities are more widely recognized and used throughout our customer base, we believe our growth will accelerate. We are particularly proud that more than 400 CEOs, including Fortune 500 CEOs, are using Domo to manage their business, with more than half doing so from their mobile device,” added James.

“Q2 was a strong quarter for us,” said Bruce Felt, CFO. “We improved execution across all functions of the organization. We are pleased with the productivity gains from sales and marketing. We believe, as we displayed this quarter, there is leverage throughout the entire organization to efficiently drive growth.”

GUIDANCE:

Domo sees FY2019 EPS of ($9.55)-($9.50), versus the consensus of $0.00. Domo sees FY2019 revenue of $136.7-137.1 million, versus the consensus of $131.38 million.

For earnings history and earnings-related data on Domo (DOMO) click here.

Categories

Earnings Guidance Hot Guidance Management Comments

Next Articles